

Jan P Dutz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8633917/publications.pdf>

Version: 2024-02-01

123
papers

5,642
citations

81900

39
h-index

85541

71
g-index

126
all docs

126
docs citations

126
times ranked

7748
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral tofacitinib citrate for recalcitrant cutaneous lupus. <i>JAAD Case Reports</i> , 2022, 20, 61-64.	0.8	14
2	Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H. <i>Rheumatology and Therapy</i> , 2022, 9, 109-125.	2.3	6
3	A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes. <i>Immunotherapy Advances</i> , 2022, 2, Itab022.	3.0	5
4	Cutaneous CpG adjuvant conditioning to enhance vaccine responses. <i>Vaccine</i> , 2022, , .	3.8	1
5	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. <i>Dermatology and Therapy</i> , 2022, 12, 253-265.	3.0	2
6	A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 13-16.	0.7	5
7	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. <i>Dermatology and Therapy</i> , 2022, 12, 1073-1089.	3.0	1
8	Psoriasis Prevalence and Severity by Expert Elicitation. <i>Dermatology and Therapy</i> , 2021, 11, 1053-1064.	3.0	28
9	An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1652-1666.	1.2	38
10	Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: fevers, myalgia, arthralgia, auricular chondritis, and erythema nodosum. <i>Lancet, The</i> , 2021, 398, 621.	13.7	22
11	Response to comment on "An evidence-based guide to SARS-Cov-2 vaccination of patients on immunotherapies in dermatology." <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e91.	1.2	1
12	Small plaque psoriasis revisited: A type of psoriasis mediated by a type I interferon pathway. <i>Experimental Dermatology</i> , 2021, , .	2.9	1
13	Corticosteroid application prior to nickel exposure prevents contact dermatitis in sensitized individuals. <i>Contact Dermatitis</i> , 2020, 82, 170-173.	1.4	1
14	Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte variant hypereosinophilic syndrome. <i>British Journal of Haematology</i> , 2020, 188, e68-e72.	2.5	13
15	Prevention of allopurinol-associated adverse cutaneous drug reactions in high-risk patient groups in Canada. <i>Cmaj</i> , 2020, 192, E168-E168.	2.0	0
16	Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 406-417.	1.4	3
17	Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1481-1488.	3.4	28
18	Recurrent sterile abscesses in a case of X-linked neutropenia. <i>Pediatric Dermatology</i> , 2020, 37, 742-744.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. <i>International Journal of Dermatology</i> , 2020, 59, 1043-1056.	1.0	19
20	<i>HLA-B*58:01</i> Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol—A Canadian Missed Opportunity. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 595-601.	1.2	12
21	New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus. <i>JAAD Case Reports</i> , 2019, 5, 682-685.	0.8	9
22	Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid. <i>JAAD Case Reports</i> , 2019, 5, 660-662.	0.8	8
23	Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1985739.	0.3	3
24	Topical Adjuvant Application during Subcutaneous Vaccination Promotes Resident Memory T Cell Generation. <i>Journal of Immunology</i> , 2019, 203, 2443-2450.	0.8	7
25	Skin Exposure to Narrow Band Ultraviolet (UVB) Light Modulates the Human Intestinal Microbiome. <i>Frontiers in Microbiology</i> , 2019, 10, 2410.	3.5	84
26	Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 437-438.	2.0	2
27	Treg gene signatures predict and measure type 1 diabetes trajectory. <i>JCI Insight</i> , 2019, 4, .	5.0	18
28	Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results. <i>Burns</i> , 2018, 44, 807-815.	1.9	38
29	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , 2018, 45, 378-384.	2.0	45
30	Nomenclature of Cutaneous Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 171-184.	5.6	200
31	CS-36—Recommendations for the assessment of systemic lupus erythematosus in Canada. , 2018, , .		0
32	Methotrexate—The Value of Case Series for Older Drugs. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 537-537.	1.2	2
33	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	2.0	43
34	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 261-267.	1.2	48
35	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , 2017, 44, 519-534.	2.0	18
36	Finger pad tophi in a patient with Raynaud phenomenon. <i>JAAD Case Reports</i> , 2017, 3, 45-48.	0.8	4

#	ARTICLE	IF	CITATIONS
37	IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series. <i>European Journal of Haematology</i> , 2017, 98, 378-387.	2.2	35
38	Case Series: A Kindred With Eruptive Vellus Hair Cysts and Systemic Features. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 564-567.	1.2	5
39	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 711-714.	1.3	7
40	Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 38.	2.0	7
41	Dr. Roubille, et al reply. <i>Journal of Rheumatology</i> , 2016, 43, 993-994.	2.0	0
42	Development and Validation of an Artificial Mechanical Skin Model for the Study of Interactions between Skin and Microneedles. <i>Macromolecular Materials and Engineering</i> , 2016, 301, 306-314.	3.6	25
43	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. <i>International Journal of Women's Dermatology</i> , 2016, 2, 44-45.	2.0	5
44	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. <i>American Journal of Medicine</i> , 2016, 129, 1221-1225.	1.5	56
45	Identification of Autoantigen Epitopes in Alopecia Areta. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1617-1626.	0.7	69
46	Cyclosporine Treatment of Drug-Induced Hypersensitivity Syndrome. <i>JAMA Dermatology</i> , 2016, 152, 1254.	4.1	59
47	Tolerogenic effect of mouse fibroblasts on dendritic cells. <i>Immunology</i> , 2016, 148, 22-33.	4.4	19
48	Psoriasis and Smoking. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 221-227.	1.2	49
49	Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 153-166.	1.4	4
50	Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. <i>ISME Journal</i> , 2016, 10, 321-332.	9.8	140
51	Meta-Analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials. <i>Arthritis Care and Research</i> , 2015, 67, 754-764.	3.4	46
52	Amyopathic Dermatomyositis-Related Thrombophilia. <i>JAMA Dermatology</i> , 2015, 151, 559.	4.1	4
53	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 480-489.	0.9	671
54	Think beyond the Skin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 22-27.	1.2	31

#	ARTICLE	IF	CITATIONS
55	Response to: "Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?" TM by Dr Boers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e34-e34.	0.9	2
56	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. <i>Journal of Rheumatology</i> , 2015, 42, 1767-1780.	2.0	113
57	D-Dimer Levels as a Marker of Cutaneous Disease Activity. <i>JAMA Dermatology</i> , 2014, 150, 880.	4.1	9
58	Atrophie Blanche. <i>Advances in Skin and Wound Care</i> , 2014, 27, 518-524.	1.0	17
59	The Immunopathology of Cutaneous Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 455-474.	1.9	26
60	Targeting the IL-17/IFN- γ axis as a potential new clinical therapy for type 1 diabetes. <i>Clinical Immunology</i> , 2014, 154, 84-89.	3.2	40
61	Topical CpG Adjuvantation of a Protein-Based Vaccine Induces Protective Immunity to <i>Listeria monocytogenes</i> . <i>Vaccine Journal</i> , 2014, 21, 329-339.	3.1	12
62	Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 941-947.	1.2	144
63	Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. <i>Oncotarget</i> , 2014, 5, 4418-4425.	1.8	55
64	Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 546-556.	2.0	7
65	Microbiota Regulates Intestinal Inflammation, Th17 Immunity and Barrier Function in the Non-obese Diabetic Mouse. <i>Canadian Journal of Diabetes</i> , 2012, 36, S60.	0.8	0
66	Molecular Markers of Early-Stage Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1698-1706.	0.7	88
67	Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin. <i>PLoS ONE</i> , 2012, 7, e51040.	2.5	83
68	Type 1 IFN- α -induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. <i>Experimental Dermatology</i> , 2012, 21, 417-419.	2.9	35
69	Quality of Life in Patients with Immune-Mediated Inflammatory Diseases. <i>Journal of rheumatology Supplement, The</i> , 2011, 88, 7-19.	2.2	20
70	Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. <i>Diabetologia</i> , 2011, 54, 1407-1416.	6.3	38
71	Collagen Triple Helix Repeat Containing 1 Promotes Melanoma Cell Adhesion and Survival. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 103-110.	1.2	30
72	Usefulness of Interferon- γ Release Assays in the Diagnosis of Erythema Induratum. <i>Archives of Dermatology</i> , 2011, 147, 949.	1.4	12

#	ARTICLE	IF	CITATIONS
73	Psychiatric Disorders in Patients with Immune-Mediated Inflammatory Diseases: Prevalence, Association with Disease Activity, and Overall Patient Well-being. <i>Journal of rheumatology Supplement, The</i> , 2011, 88, 31-35.	2.2	35
74	Cigarette Smoking and Response to Antimalarials in Cutaneous Lupus Erythematosus Patients: Evolution of a Dogma. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1968-1970.	0.7	27
75	Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. <i>Blood</i> , 2010, 116, 5748-5751.	1.4	70
76	Gut barrier disruption by an enteric bacterial pathogen accelerates insulinitis in NOD mice. <i>Diabetologia</i> , 2010, 53, 741-748.	6.3	114
77	TLR9 Blockade Inhibits Activation of Diabetogenic CD8+ T Cells and Delays Autoimmune Diabetes. <i>Journal of Immunology</i> , 2010, 184, 5645-5653.	0.8	70
78	Expansion of Antigen-Specific Regulatory T Cells with the Topical Vitamin D Analog Calcipotriol. <i>Journal of Immunology</i> , 2009, 182, 6071-6078.	0.8	127
79	Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. <i>International Immunology</i> , 2009, 21, 757-767.	4.0	21
80	Murine models of cutaneous involvement in lupus erythematosus. <i>Autoimmunity Reviews</i> , 2009, 8, 484-487.	5.8	28
81	T-Cell-Mediated Injury to Keratinocytes: Insights from Animal Models of the Lichenoid Tissue Reaction. <i>Journal of Investigative Dermatology</i> , 2009, 129, 309-314.	0.7	17
82	Topical resiquimod promotes priming of CTL to parenteral antigens. <i>Vaccine</i> , 2009, 27, 5791-5799.	3.8	39
83	Islet Allograft Rejection Is Independent of Toll-Like Receptor Signaling in Mice. <i>Transplantation</i> , 2009, 88, 1075-1080.	1.0	22
84	Topical CpG Enhances the Response of Murine Malignant Melanoma to Dacarbazine. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2204-2210.	0.7	24
85	IFN- γ -mediated extravillous trophoblast outgrowth inhibition in first trimester explant culture: a role for insulin-like growth factors. <i>Molecular Human Reproduction</i> , 2008, 14, 281-289.	2.8	31
86	Better Influenza Vaccines for Older People: What Will It Take?. <i>Journal of Infectious Diseases</i> , 2008, 198, 632-634.	4.0	61
87	Development of a Modified Skin Explant Assay to Study Treg Suppression of Th17 Cell Mediated GvHD in the Skin. <i>Blood</i> , 2008, 112, 5434-5434.	1.4	0
88	Clinical and genetic registries in psoriatic disease. <i>Journal of Rheumatology</i> , 2008, 35, 1458-63.	2.0	8
89	Psoriasiform Eruptions During Anti-TNF- α Treatment: Psoriasis or Not? Reply. <i>Archives of Dermatology</i> , 2007, 143, 1589.	1.4	4
90	Psoriasis and Pustular Dermatitis Triggered by TNF- α Inhibitors in Patients With Rheumatologic Conditions. <i>Archives of Dermatology</i> , 2007, 143, 223-31.	1.4	291

#	ARTICLE	IF	CITATIONS
91	Treatment of Atypical Nevi With Imiquimod 5% Cream. Archives of Dermatology, 2007, 143, 379-85.	1.4	12
92	Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. European Journal of Immunology, 2007, 37, 2242-2256.	2.9	20
93	New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy, 2007, 20, 160-174.	1.7	234
94	Pathophysiology of Cutaneous Lupus Erythematosus. Clinical Reviews in Allergy and Immunology, 2007, 33, 85-106.	6.5	102
95	Tumor necrosis factor- α inhibition and palmoplantar pustulosis: Janus-faced therapy?. Journal of Rheumatology, 2007, 34, 247-9.	2.0	14
96	Decidual NK Cells Alter In Vitro First Trimester Extravillous Cytotrophoblast Migration: A Role for IFN- γ . Journal of Immunology, 2006, 177, 8522-8530.	0.8	122
97	Sclerotic skin disease: when smooth skin is unwelcome. Expert Review of Dermatology, 2006, 1, 487-492.	0.3	0
98	The Skin as a Site of Initiation of Systemic Autoimmune Disease: New Opportunities for Treatment. Journal of Investigative Dermatology, 2006, 126, 1209-1212.	0.7	0
99	Tolerance Induction by Transcutaneous Immunization through Ultraviolet-Irradiated Skin Is Transferable through CD4+CD25+ T Regulatory Cells and Is Dependent on Host-Derived IL-10. Journal of Immunology, 2006, 176, 2635-2644.	0.8	77
100	A Novel T Cell Receptor Transgenic Animal Model of Seborrheic Dermatitis-Like Skin Disease. Journal of Investigative Dermatology, 2005, 124, 151-159.	0.7	18
101	Cutting Edge: Signaling Lymphocytic Activation Molecule-Associated Protein Controls NKT Cell Functions. Journal of Immunology, 2005, 174, 3153-3157.	0.8	160
102	Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. International Immunology, 2004, 16, 1657-1662.	4.0	17
103	Regulation of Autoimmune Diabetes by Complete Freund's Adjuvant Is Mediated by NK Cells. Journal of Immunology, 2004, 172, 937-942.	0.8	96
104	Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL. Journal of Investigative Dermatology, 2004, 122, 1042-1049.	0.7	45
105	Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine, 2004, 22, 1985-1991.	3.8	43
106	Mycophenolate Mofetil (CellCept $\frac{1}{2}$) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. Journal of Cutaneous Medicine and Surgery, 2003, 7, 193-197.	1.2	24
107	Skin immune responses to peptide and protein antigen are TLR4 independent. Cellular Immunology, 2003, 226, 116-123.	3.0	6
108	Optimization of epicutaneous immunization for the induction of CTL. Vaccine, 2003, 21, 2890-2899.	3.8	65

#	ARTICLE	IF	CITATIONS
109	Mycophenolate Mofetil (CellCept®) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 193-197.	1.2	38
110	Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. <i>Journal of Clinical Investigation</i> , 2003, 111, 217-223.	8.2	108
111	In Situ \hat{I}^2 Cell Death Promotes Priming of Diabetogenic CD8 T Lymphocytes. <i>Journal of Immunology</i> , 2002, 168, 1466-1472.	0.8	96
112	Phagocytosis of Apoptotic Cells by Macrophages From NOD Mice Is Reduced. <i>Diabetes</i> , 2002, 51, 2481-2488.	0.6	134
113	Lymphocytic vasculitis in X-linked lymphoproliferative disease. <i>Blood</i> , 2001, 97, 95-100.	1.4	73
114	The pathophysiology of photosensitivity in lupus erythematosus. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2001, 17, 95-113.	1.5	40
115	Cutting Edge: Defective NK Cell Activation in X-Linked Lymphoproliferative Disease. <i>Journal of Immunology</i> , 2000, 165, 3549-3553.	0.8	146
116	Crusted Scabies in Association with Human T-Cell Lymphotropic Virus 1. <i>Journal of Cutaneous Medicine and Surgery</i> , 1999, 3, 148-152.	1.2	20
117	IMMUNOSUPPRESSIVE AGENTS IN DERMATOLOGY. <i>Dermatologic Clinics</i> , 1998, 16, 235-251.	1.7	86
118	A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. <i>International Journal of Dermatology</i> , 1998, 37, 51-53.	1.0	8
119	Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 1997, 9, 400-409.	4.3	35
120	Immunosuppressive Agents in Skin Disorders. <i>BioDrugs</i> , 1996, 5, 268-293.	0.7	11
121	Fas (CD95)-independent regulation of immune responses by antigen-specific CD4 \hat{I} CD8+ T cells. <i>International Immunology</i> , 1996, 8, 675-681.	4.0	22
122	A cytotoxic T lymphocyte clone can recognize the same naturally occurring self peptide in association with a self and a nonself class I MHC protein. <i>Molecular Immunology</i> , 1994, 31, 967-975.	2.2	29
123	Effects of cognate peptides on cytolytic and proliferative activities of cloned cytotoxic T lymphocytes. <i>International Immunology</i> , 1992, 4, 571-580.	4.0	21